Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by MrMonkon Jun 07, 2013 10:13am
210 Views
Post# 21500375

Comments from Aurizon CEO

Comments from Aurizon CEO

Just got this from Aurizon's CEO - we speak on e-mail from time to time: 

The timing of Marban is now with Hecla Mining Company, and I  am unsure of what their intention is, but they are probably awaiting the Phase 2 drilling resource update. I do know Hecla have started to visit the properties in Quebec and familiarize themselves further with all of the assets.

Let's see if Hecla sees the obviously value in Marban.  They're going to have to make a decision in the next several months on Phase 3 and I'm sure the updated 43-101 is going to impact that decision.

Are you in or are you out?  Either way, this thing will become a mine and producing precious metals companies don't typically $20 million market caps!

 

- MM

 

<< Previous
Bullboard Posts
Next >>